HUP0300974A2 - Ciklin-dependens kinázok N-{5-[(5--alkil-2-oxazolil)-metil-tio]-2-tiazolil}-karboxamid inhibitorai, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents
Ciklin-dependens kinázok N-{5-[(5--alkil-2-oxazolil)-metil-tio]-2-tiazolil}-karboxamid inhibitorai, ezeket tartalmazó gyógyszerkészítmények és alkalmazásukInfo
- Publication number
- HUP0300974A2 HUP0300974A2 HU0300974A HUP0300974A HUP0300974A2 HU P0300974 A2 HUP0300974 A2 HU P0300974A2 HU 0300974 A HU0300974 A HU 0300974A HU P0300974 A HUP0300974 A HU P0300974A HU P0300974 A2 HUP0300974 A2 HU P0300974A2
- Authority
- HU
- Hungary
- Prior art keywords
- alkyl
- group
- general formula
- oxazolyl
- thiazolyl
- Prior art date
Links
- 108091007914 CDKs Proteins 0.000 title 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 title 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A találmány tárgyát az általános képletű vegyületek - ahol Ralkilcsoport; R1 és R2 hidrogénatom vagy alkilcsoport; R3 jelentésehidrogénatom vagy alkilcsoport, és R4 jelentése hidrogénatom vagy egyvagy két hidroxicsoporttal szubsztituált alkilcsoport, vagy egy -NR5R6általános képletű csoport, vagy R3 és R4 a kapcsolódó nitrogénatommalegyütt 4-7 tagú heterociklikus gyűrűt képez, ahol R3R4 olyan -(CH2)náltalános képletű csoport, ahol n = 3, 4, 5 vagy 6; R5 és R6hidrogénatom, adott esteben szubsztituált alkil- vagycikloalkilcsoport, vagy R5 és R6 a kapcsolódó nitrogénatommal együtt4-7-tagú heterociklikus gyűrűt képez, ahol R5R6 jelentése -(CH2)m-általános képletű csoport, ahol m = 3, 4, 5 vagy 6; és X =CH-csoportvagy nitrogénatom - és enantiomereik, diaszteromereik ésgyógyszerészetileg elfogadható sóik képezik. A találmány kiterjed avegyületeket tartalmazó gyógyszerkészítményekre és ezek alkalmazására. Ó
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/464,511 US6262096B1 (en) | 1997-11-12 | 1999-12-15 | Aminothiazole inhibitors of cyclin dependent kinases |
| US09/616,629 US6214852B1 (en) | 1998-10-21 | 2000-07-26 | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
| PCT/US2000/033113 WO2001044241A1 (en) | 1999-12-15 | 2000-12-07 | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0300974A2 true HUP0300974A2 (hu) | 2003-08-28 |
| HUP0300974A3 HUP0300974A3 (en) | 2009-03-30 |
Family
ID=27041009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0300974A HUP0300974A3 (en) | 1999-12-15 | 2000-12-07 | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases, pharmaceutical compositions containing them and their use |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6214852B1 (hu) |
| EP (1) | EP1240165B1 (hu) |
| JP (1) | JP2003525872A (hu) |
| KR (1) | KR20020067547A (hu) |
| CN (1) | CN1433415A (hu) |
| AT (1) | ATE294800T1 (hu) |
| AU (1) | AU774381B2 (hu) |
| CA (1) | CA2394544A1 (hu) |
| CO (1) | CO5251464A1 (hu) |
| CZ (1) | CZ20022013A3 (hu) |
| DE (1) | DE60019964T2 (hu) |
| DK (1) | DK1240165T3 (hu) |
| EE (1) | EE200200306A (hu) |
| ES (1) | ES2241678T3 (hu) |
| HU (1) | HUP0300974A3 (hu) |
| PE (1) | PE20010932A1 (hu) |
| PL (1) | PL364884A1 (hu) |
| PT (1) | PT1240165E (hu) |
| SI (1) | SI20975B (hu) |
| TW (1) | TWI265930B (hu) |
| UY (1) | UY26480A1 (hu) |
| WO (1) | WO2001044241A1 (hu) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6262096B1 (en) | 1997-11-12 | 2001-07-17 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| US6414156B2 (en) | 1998-10-21 | 2002-07-02 | Bristol-Myers Squibb Company | Process for preparing azacycloalkanoylaminothiazoles |
| US6515004B1 (en) | 1999-12-15 | 2003-02-04 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
| US6392053B2 (en) * | 1999-12-15 | 2002-05-21 | Bristol-Myers Squibb Company | Process for preparing arylacetylaminothiazoles |
| US6534531B2 (en) * | 2000-04-27 | 2003-03-18 | Bristol-Myers Squibb Company | Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy |
| EP1724270A3 (en) * | 2001-07-19 | 2007-01-03 | Pfizer Italia S.r.l. | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
| CA2453294A1 (en) * | 2001-07-19 | 2003-01-30 | Paolo Pevarello | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
| ES2183734B1 (es) * | 2001-08-02 | 2004-06-16 | Consejo Sup. Investigaciones Cientificas | Derivados de 4-4'-bipiridil-2-2'-bisoxazoles y 4-4'-bipiridil-2-2'-bistiazoles como agentes antineoplasicos. |
| JP2004538315A (ja) * | 2001-08-03 | 2004-12-24 | ノボ・ノルデイスク・エー／エス | 新規の２，４−ジアミノチアゾール誘導体 |
| CN1547574A (zh) * | 2001-08-03 | 2004-11-17 | ŵ��Ų�ڿ˹�˾ | 新型2,4-二氨基噻唑衍生物 |
| TW200401638A (en) * | 2002-06-20 | 2004-02-01 | Bristol Myers Squibb Co | Heterocyclic inhibitors of kinases |
| DE10300124A1 (de) * | 2003-01-07 | 2004-07-15 | Bayer Ag | Verfahren zur Herstellung von Arylalkinen |
| US20070105114A1 (en) * | 2003-07-29 | 2007-05-10 | Martha Li | Biomarkers of cyclin-dependent kinase modulation |
| US7888504B2 (en) * | 2006-07-06 | 2011-02-15 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
| WO2008049856A2 (en) * | 2006-10-25 | 2008-05-02 | Ingenium Pharmaceuticals Gmbh | Methods of treating pain using cdk inhibitors |
| CA2784807C (en) | 2009-12-29 | 2021-12-14 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| MX342746B (es) * | 2011-09-28 | 2016-10-11 | Euro-Celtique S A * | Derivados de mostaza de nitrogeno. |
| US9382239B2 (en) | 2011-11-17 | 2016-07-05 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-terminal kinase (JNK) |
| AR092790A1 (es) | 2012-02-01 | 2015-05-06 | Euro Celtique Sa | Derivados bencimidazolicos del acido hidroxamico |
| EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| EP3057956B1 (en) | 2013-10-18 | 2021-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
| US20160264551A1 (en) | 2013-10-18 | 2016-09-15 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
| GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| WO2016105528A2 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| US10550121B2 (en) | 2015-03-27 | 2020-02-04 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| AU2016276963C1 (en) | 2015-06-12 | 2021-08-05 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| EP4019515A1 (en) * | 2015-09-09 | 2022-06-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| AU2016426574B2 (en) | 2016-10-11 | 2023-07-13 | Euro-Celtique S.A. | Hodgkin lymphoma therapy |
| GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
| GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
| GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
| GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1088049A (en) | 1975-06-03 | 1980-10-21 | Takashi Masugi | 3-substituted-7-substituted alkanamido-3-cephem-4- carboxylic acid compounds and processes for preparation thereof |
| CA1201431A (en) | 1981-12-17 | 1986-03-04 | Daiei Tunemoto | .beta.-LACTAM COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND INTERMEDIATE PRODUCTS FOR THE PREPARATION THEREOF |
| TW205041B (hu) | 1989-08-07 | 1993-05-01 | Fujisawa Pharmaceutical Co | |
| US5491157A (en) | 1993-05-10 | 1996-02-13 | Eastman Kodak Company | Method and composition for the prevention, control and amelioration of soilborne fungi and disease caused thereby |
| IL112721A0 (en) | 1994-03-10 | 1995-05-26 | Zeneca Ltd | Azole derivatives |
| EP0796263A1 (en) | 1994-12-09 | 1997-09-24 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds and pharmaceutical use thereof |
| IL117620A0 (en) | 1995-03-27 | 1996-07-23 | Fujisawa Pharmaceutical Co | Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same |
| AUPN801196A0 (en) | 1996-02-12 | 1996-03-07 | Fujisawa Pharmaceutical Co., Ltd. | New cephem compounds and pharmaceutical use thereof |
| GEP20032896B (en) | 1997-10-27 | 2003-02-25 | Agouron Pharma | 4-Aminothiazole Derivatives, Containing Them Pharmaceutical Compositions Inhibiting Cyclin-Dependent Kinases and Methods for Treatment |
| US6040321A (en) | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| GB9823871D0 (en) | 1998-10-30 | 1998-12-23 | Pharmacia & Upjohn Spa | 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents |
-
2000
- 2000-07-26 US US09/616,629 patent/US6214852B1/en not_active Expired - Lifetime
- 2000-12-07 DK DK00982481T patent/DK1240165T3/da active
- 2000-12-07 AT AT00982481T patent/ATE294800T1/de active
- 2000-12-07 PL PL00364884A patent/PL364884A1/xx not_active Application Discontinuation
- 2000-12-07 SI SI200020060A patent/SI20975B/sl not_active IP Right Cessation
- 2000-12-07 DE DE60019964T patent/DE60019964T2/de not_active Expired - Lifetime
- 2000-12-07 CA CA002394544A patent/CA2394544A1/en not_active Abandoned
- 2000-12-07 ES ES00982481T patent/ES2241678T3/es not_active Expired - Lifetime
- 2000-12-07 PT PT00982481T patent/PT1240165E/pt unknown
- 2000-12-07 EE EEP200200306A patent/EE200200306A/xx unknown
- 2000-12-07 WO PCT/US2000/033113 patent/WO2001044241A1/en active Search and Examination
- 2000-12-07 JP JP2001544731A patent/JP2003525872A/ja active Pending
- 2000-12-07 CN CN00818899A patent/CN1433415A/zh active Pending
- 2000-12-07 HU HU0300974A patent/HUP0300974A3/hu unknown
- 2000-12-07 EP EP00982481A patent/EP1240165B1/en not_active Expired - Lifetime
- 2000-12-07 AU AU19506/01A patent/AU774381B2/en not_active Ceased
- 2000-12-07 KR KR1020027007617A patent/KR20020067547A/ko not_active Application Discontinuation
- 2000-12-07 CZ CZ20022013A patent/CZ20022013A3/cs unknown
- 2000-12-11 TW TW089126395A patent/TWI265930B/zh not_active IP Right Cessation
- 2000-12-14 UY UY26480A patent/UY26480A1/es not_active Application Discontinuation
- 2000-12-14 CO CO00095239A patent/CO5251464A1/es not_active Application Discontinuation
- 2000-12-15 PE PE2000001348A patent/PE20010932A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CZ20022013A3 (cs) | 2003-03-12 |
| JP2003525872A (ja) | 2003-09-02 |
| TWI265930B (en) | 2006-11-11 |
| AU1950601A (en) | 2001-06-25 |
| PT1240165E (pt) | 2005-09-30 |
| DE60019964T2 (de) | 2006-04-27 |
| EP1240165A1 (en) | 2002-09-18 |
| CA2394544A1 (en) | 2001-06-21 |
| AU774381B2 (en) | 2004-06-24 |
| CN1433415A (zh) | 2003-07-30 |
| US6214852B1 (en) | 2001-04-10 |
| EE200200306A (et) | 2003-06-16 |
| PL364884A1 (en) | 2004-12-27 |
| DE60019964D1 (en) | 2005-06-09 |
| KR20020067547A (ko) | 2002-08-22 |
| SI20975B (sl) | 2006-04-30 |
| ATE294800T1 (de) | 2005-05-15 |
| WO2001044241A1 (en) | 2001-06-21 |
| SI20975A (sl) | 2003-02-28 |
| DK1240165T3 (da) | 2005-08-08 |
| HUP0300974A3 (en) | 2009-03-30 |
| UY26480A1 (es) | 2001-07-31 |
| ES2241678T3 (es) | 2005-11-01 |
| PE20010932A1 (es) | 2001-11-18 |
| EP1240165B1 (en) | 2005-05-04 |
| CO5251464A1 (es) | 2003-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0300974A2 (hu) | Ciklin-dependens kinázok N-{5-[(5--alkil-2-oxazolil)-metil-tio]-2-tiazolil}-karboxamid inhibitorai, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0004259A2 (hu) | VLA-4 által mediált leukocita adhéziót gátló szubsztituált fenilalanin-származékok, ezeket tartalmazó gyógyászati készítmények | |
| TR200101884T2 (tr) | Farnesil transferaz inhibitörleri olarak 4-merkaptopirolidin türevleri. | |
| HUP0302969A2 (hu) | NPY Y5 antagonisták, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0100388A2 (hu) | Készítmények és eljárások csontritkulás kezelésére és a koleszterinszint csökkentésére | |
| HUP0004595A2 (hu) | Aciklikus metalloproteáz inhibitorok | |
| NO940737D0 (no) | Antidepressive midler | |
| HUP0300641A2 (hu) | Triazaspiro[5.5]undekán-származékok és hatóanyagként ezeket tartalmazó gyógyszerkészítmények | |
| HUP0004531A2 (hu) | VLA-4 által mediált leukocita adhéziót gátló 4-aminofenilalanin-vegyületek, ezeket tartalmazó gyógyászati készítmények, valamint alkalmazásuk | |
| HUP0004529A2 (hu) | VLA-4 által mediált leukocita adhéziót gátló szulfonilezett dipeptid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint alkalmazásuk | |
| HUP9900790A2 (hu) | Imidazo-kinazolin-származékok | |
| DE69505968T2 (de) | Azolidindion-derivate und ihre anwendung als antihyperglykämika | |
| AR030563A1 (es) | N-[5-[[[5-alquil-2-oxazolil]metil]tio]-2-tiazolil]carboxamidas inhibidoras de cinasas dependientes de la ciclina y composiciones farmaceuticas que las contienen | |
| HUP0301032A2 (hu) | Ciklin-dependens kinázok N-{5-[(5-alkil-2-oxazolil)-metil-tio]-2-tiazolil}-karboxamid inhibitorai, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0002239A2 (hu) | Tieno-pirimidin-származékok alkalmazása gombák leküzdésére | |
| AU591390B2 (en) | Arylcyclobutylalkyl amines and their use as antidepressive medicines | |
| HUP9903590A2 (hu) | 3-(Azetidinil-alkil)-piperidin- vagy -pirrolidin-származékok mint tachikinin-antagonisták | |
| NZ330078A (en) | Active oxygen carriers containing pterin derivatives and salts thereof for use as cosmetic agents and feed | |
| HUP9802995A2 (hu) | Szubsztituált szulfonil-amino-(tio)karbonil-származékok, intermedierjeik, a vegyületeket hatóanyagként tartalmazó herbicid készítmények, valamint eljárás a vegyületek, és készítmények előállítására és alkalmazására | |
| HUP0301030A2 (hu) | Kardiális aritmiák kezelésére alkalmazható új aza-biciklooktán-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| IL108258A0 (en) | Piperazine derivates, their preparation and pharmaceutical compositions containing them | |
| BR9913183A (pt) | Composto, uso do mesmo, processo para prepará-lo, processo para tratar um indivìduo humano ou animal, e, composição farmacêutica | |
| ZA948082B (en) | 1,2,3,4-tetrahydronaphthalene compounds, process for their preparation and the pharmaceutical compositions which contain them. | |
| HUP0105407A2 (hu) | Triazolo[1,5-a]kinolinszármazékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények, valamint intermedierek | |
| NO308532B1 (no) | Farmasøytiske piperazinforbindelser |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |